Phase i trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

Cancer Immunology, Immunotherapy

Volumn 62, Issue 1, 2013, Pages 125-135

  Phuphanich, Surasak ^a   Wheeler, Christopher J ^a   Rudnick, Jeremy D ^a   Mazer, Mia ^a   Wang, Hongqian ^a   Nuño, Miriam A ^a   Richardson, Jaime E ^a   Fan, Xuemo ^a   Ji, Jianfei ^a   Chu, Ray M ^a   Bender, James G ^b   Hawkins, Elma S ^b   Patil, Chirag G ^a   Black, Keith L ^a   Yu, John S ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b ImmunoCellular Therapeutics Ltd   (United States)

Author keywords

Cancer stem cells; Cancer vaccine; CTL; Dendritic cell immunotherapy; Epitopes; Glioblastoma

Indexed keywords

BEVACIZUMAB; CD133 ANTIGEN; CEDIRANIB; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GLYCOPROTEIN GP 100; HLA A1 ANTIGEN; HLA A2 ANTIGEN; INTERLEUKIN 13 RECEPTOR ALPHA2; IRINOTECAN; MELANOMA ANTIGEN 1; PROTEIN AIM 2; RECOMBINANT GAMMA INTERFERON; TEMOZOLOMIDE; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER FATIGUE; CANCER IMMUNIZATION; CANCER STEM CELL; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RESPONSE; DENDRITIC CELL; DIARRHEA; DOWN REGULATION; DRUG EFFICACY; DRUG ERUPTION; FEMALE; FLUSHING; FOLLOW UP; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKAPHERESIS; MALE; MONONUCLEAR CELL; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; SKIN REDNESS; SURVIVAL RATE; TUMOR IMMUNITY; TUMOR RECURRENCE; VOMITING;

ADULT; AGED; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CANCER VACCINES; DENDRITIC CELLS; EPITOPES; FEMALE; GLIOBLASTOMA; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84872498982     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1319-0     Document Type: Article

References (30)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
2. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S et al (2008) Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68:5955-5964
3. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH et al (2010) Gene expression profile correlates with T cell infiltration and survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res
4. Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ (2008) Reengineering dendritic cell-based anti-cancer vaccines. Immunol Rev 222:256-276
5. Schuler G, Schuler-Thurner B, Steinman RM (2003) The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138-147
6. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973-4979
7. Okada H (2009) Brain tumor immunotherapy with type-1 polarizing strategies. Ann N Y Acad Sci 1174:18-23
8. Ardon H, Van GS, Lopes IS, Maes W, Sciot R, Wilms G et al (2010) Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol 99:261-272
9. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK et al (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842-847
10. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821-5828
11. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL et al (2004) Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23:9392-9400
12. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492-507
13. Tamura K, Aoyagi M, Wakimoto H, Ando N, Nariai T, Yamamoto M et al (2010) Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. J Neurosurg 113:310-318
14. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR et al (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67
15. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N et al (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14:123-129
16. Pallini R, Ricci-Vitiani L, Montano N, Mollinari C, Biffoni M, Cenci T et al (2011) Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer 117:162-174
17. Xu Q, Liu G, Yuan X, Xu M, Wang H, Ji J et al (2009) Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 27:1734-1740
18. Ghods AJ, Irvin D, Liu G, Yuan X, Abdulkadir IR, Tunici P et al (2007) Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells 25:1645-1653
19. Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S et al (2007) Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res 13:566-575
20. Saikali S, Avril T, Collet B, Hamlat A, Bansard JY, Drenou B et al (2007) Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol 81:139-148
21. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS (2004) HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 64:4980-4986
22. Liu G, Khong HT, Wheeler CJ, Yu JS, Black KL, Ying H (2003) Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma. J Immunother 26:301-312
23. Liu G, Yu JS, Zeng G, Yin D, Xie D, Black KL et al (2004) AIM-2: a novel tumor antigen is expressed and presented by human glioma cells. J Immunother 27:220-226
24. Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H (2002) Identification of a novel HLA-A0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 8:2851-2855
25. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408
26. Vlassenbroeck I, Califice S, Diserens AC, Migliavacca E, Straub J, Di Stefano I et al (2008) Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 10:332-337
27. van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ et al (2011) Harmonization of immune biomarker assays for clinical studies. Sci Transl Med 3:108ps44
28. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE et al (2011) Induction of CD8+ T-Cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29:330-336
29. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722-4729
30. Irvin DK, Jouanneau E, Duvall G, Zhang XX, Zhai Y, Sarayba D et al (2010) T cells enhance stem-like properties and conditional malignancy in gliomas. PLoS One 5:e10974